

14 July 2025

**CVS Group plc**  
("CVS" or the "Company")

**Block Listing Interim Review**

CVS, the UK's listed veterinary group and a leading provider of veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements. References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").

Name of the company:		CVS Group plc		
Name of relevant scheme:		1. CVS Group SAYE Plan; and 2. CVS Long Term Incentive Plan		
Period of return:	From:	12 January 2025	To:	12 July 2025
Balance of unallotted securities under scheme(s) from previous return:		1. 337,965 2. 68,393		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1. Nil 2. Nil		
Less: Number of securities issued / allotted under scheme(s) during period:		1. Nil 2. Nil		
Equals: Balance under scheme(s) not yet issued / allotted at end of period:		1. 337,965 2. 68,393		
Number and class of securities originally listed and the date of admission:		1. 350,000 Ordinary Shares admitted on 30 December 2021 2. 120,000 Ordinary Shares admitted on 15 May 2023		

**Contacts:**

**CVS Group plc**  
Richard Fairman, CEO  
Scott Morrison, Company Secretary

**via Camarco**

**Peel Hunt LLP (Nominated Adviser & Broker)**  
Christopher Golden / James Steel / Andrew Clark

**+44 (0)20 7418 8900**

**Berenberg (Joint Broker)**  
Toby Flaux / Michael Burke / James Thompson / Milo Bonser

**+44 (0)20 3207 7800**

**Camarco (Financial PR)**  
Ginny Pulbrook  
Letaba Rimell  
Tilly Butcher

**+44 (0)7961 315 138**

information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRUAAURVRUBAAR